Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.230
-0.010 (-0.81%)
Mar 9, 2026, 3:37 PM EDT - Market open
Allarity Therapeutics Employees
As of December 31, 2024, Allarity Therapeutics had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,187,286
Market Cap
19.78M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| Reviva Pharmaceuticals Holdings | 14 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| Intensity Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| NanoViricides | 7 |
| Cadrenal Therapeutics | 4 |
ALLR News
- 3 days ago - Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization - GlobeNewsWire
- 19 days ago - Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - GlobeNewsWire
- 4 weeks ago - Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - GlobeNewsWire
- 6 months ago - Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 - GlobeNewsWire
- 6 months ago - Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer - GlobeNewsWire